BST Update
BST Position Update – July 24, 2015
. . . . Progenics Pharmaceuticals (NASDAQ: $PGNX) – Hold There’s a lot to like about Progenics stock price action lately. The stock made a new high of $9.27. That’s a 69% gain from where we bought it. At a current price of $8.64, PGN is up 58%. What’s more, earnings estimates for the company […]
BST Position Update – June 11, 2015
. . . . Progenics Pharmaceuticals (NASDAQ: $PGNX) – Hold Progenics lead drug, Relistor, recently received approval from the European Commission to treat opioid-induced constipation (OIC) in all adult patients when response to laxative therapy has not been sufficient. They also received an additional year of marketing protection. The news seems to have triggered a […]
BST Position Update – April 1, 2015
. . . . Dyax (NASDAQ: DYAX) – Hold Boom! Dyax’s drug known as DX-2930, was found to have eliminated all attacks of hereditary angioedema, or HAE, when taken at doses of 300 milligrams. In others words, Dyax has found a cure for HAE. Not surprisingly, this drug is being fast tracked by the FDA. […]
BST Position Update – March 24, 2015
. . . . Merrimack Pharmaceuticals (NASDAQ: MACK) – Sell MACK hit a new high of $12.50 recently. And it’s currently trading for $11.57 per share. That’s a gain of 73% from our original buy price. And we continued to recommend accumulating shares when the stock was as low as $2.00 per share. MACK has […]
BST Position Update – February 23, 2015
. . . . Array BioPharma (NASDAQ: ARRY) – Sell Our shares of ARRY have doubled in price. The most recent uptick came after the company struck a deal to purchase a cancer treatment in late stage development. There’s clearly some big upside associated with any cancer treatment. But I think the stock has gotten […]
BST Position Update – January 16, 2015
. . . . Arena Pharmaceuticals (NASDAQ: ARNA) – Hold As I pointed out in the trade alert for Arena Pharmaceuticals, the company has a proven track record of bringing new drugs to market. And they have cash flow from the sales of BELVIQ that will help support the costs of new drug developments. One […]
BST Position Update: December 19, 2014
December 19, 2014 . . . . Cerus (NASDAQ: CERS) – Buy Cerus has caught fire over the last three days. CERS is up more than 30% this week after receiving approval from the FDA for the INTERCEPT Blood System for plasma. Obviously, that’s fantastic news for CERS. This is their first approval in the US. And […]
BST Position Update: November 7, 2014
November 7, 2014 . . . . Aeterna Zentaris (NASDAQ: AEZS) – Buy AEZS received disappointing news from the FDA this week regarding their NDA for Macrilen. In short, the FDA’s Complete Response Letter said the clinical trial didn’t support approval in its present form. At this point, the future of Macrilen is uncertain. And […]
BST Position Update: October 23, 2014
October 23, 2014 . . . . Merrimack Pharmaceuticals (NASDAQ: MACK) – Hold MACK has bucked the trend of most biotech stocks this year. It has been in a strong uptrend despite the overall weakness in small-cap biotech stocks. The stock is now at a 52-week high of $9.17. That represents a jaw dropping 347% […]
BST Market Update: October 10, 2014
October 10, 2014 Investing in developmental stage biotech stocks often feels like we’re mining for diamonds. We have to dig through tons of worthless dirt to find the few jewels that make it worth the effort. There’s no denying the rewards of biotech investing are unlike anything else when we find one of these diamonds. […]
